🇺🇸 FDA

Intelligence · Clinical Pipeline

Sanofi-Aventis U.S Pipeline

All ClinicalTrials.gov programs at Sanofi-Aventis U.S — phase, modality, and trial IDs.

Programs
117

Quick answer

Sanofi-Aventis U.S has 117 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. same excipients except no hypromellose, PREDNISONE , SAR445761 - belumosudil, PREDNISOLONE

    Sanofi-aventis Healthcare Pty Ltd

    chronic graft versus host disease

    phase 3 small molecule active

    1 trial

  2. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  3. A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 other active

    1 trial

  4. A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  5. A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth

    Sanofi-aventis Healthcare Pty Ltd

    Healthy volunteers

    phase 2 other active

    1 trial

  6. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  7. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  8. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  9. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  10. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  11. Balinatunfib, Not the same excipients as test

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease, Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  12. Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  13. Dexamethason 8 mg JENAPHARM®, SAR445761 - belumosudil, Isatuximab, Isatuximab, Dexamethason 4 mg JENAPHARM®

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  14. Frexalimab, Matched Placebo for Test

    Sanofi-aventis Healthcare Pty Ltd

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  15. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  16. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  17. Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  18. Isatuximab, Dexamethason 8 mg JENAPHARM®, Dexamethason 4 mg JENAPHARM®, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  19. Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL

    Sanofi-aventis Healthcare Pty Ltd

    Cancer - Relapsed/refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  20. Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  21. Itepekimab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Bronchiectasis

    phase 2 small molecule active

    1 trial

  22. Match Placebo to Test Product, SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 small molecule active

    1 trial

  23. Match placebo to test product, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease

    phase 2 small molecule active

    1 trial

  24. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  25. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  26. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  27. Matched placebo for test product, Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  28. Matched placebo for test product, SAR444336

    Sanofi-aventis Healthcare Pty Ltd

    Digestive system diseases

    phase 2 small molecule active

    1 trial

  29. Matched, SAR444656

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  30. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  31. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  32. Not the same excipients as Test, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  33. PEGENZILEUKIN, Isatuximab, Isatuximab

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  34. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  35. PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579

    Sanofi-aventis Healthcare Pty Ltd

    Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia

    phase 2 small molecule active

    1 trial

  36. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  37. Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  38. Rilzabrutinib, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 2 small molecule active

    1 trial

  39. SAR421869

    Sanofi-aventis Healthcare Pty Ltd

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  40. SAR422459

    Sanofi-aventis Healthcare Pty Ltd

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  41. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  42. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  43. SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  44. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  45. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  46. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  47. SAR445761 - belumosudil, belumosudil

    Sanofi-aventis Healthcare Pty Ltd

    Chronic graft versus host disease.

    phase 2 small molecule active

    1 trial

  48. Sodium Chloride 0.9%, INBRX-101 Concentrate for Solution for Infusion 50mg/ml, Respreeza 1,000 mg powder and solvent for solution for infusion.

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Sanofi-Aventis U.S have?

117 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.